The US Food and Drug Administration (FDA) has granted approval for Medtronic’s OmniaSecure defibrillation lead intended for ...

Where this device will fit in with other emerging options remains to be seen, but it might hold an advantage in large annuli.

ECU Health Medical Center is expanding advanced heart care with state-of-the-art technology for transcatheter tricuspid valve ...

At two years of follow-up, patients with a poorly functioning tricuspid valve in the heart who received the best available medical therapy plus a minimally invasive procedure using a clip to ...

Medtronic (NYSE: MDT) announced that it received FDA approval for its OmniaSecure defibrillation lead for right ventricle ...

“These new procedures represent a major advancement in the treatment of tricuspid valve regurgitation, offering hope to patients who previously had limited options,” Section Chief ...

The replacement system is launching into markets already served by repair devices, namely Edwards’ Pascal and Abbott’s ...

After acquiring its developer last year, Edwards Lifesciences has now obtained a European approval for what it described as ...

Adhering to the principles of evidence-based medicine, Venus Medtech has consistently conducted long-term follow-up studies for its registered clinical trials, generating outstanding data that ...

Edwards SAPIEN M3 mitral valve replacement system receives CE Mark for transcatheter treatment: Irvine, California Wednesday, ...

Early humanitarian use data in 20 patients with 100% severe or worse tricuspid regurgitation showed 90% reduced to ≤mild regurgitation at 30-day follow-up. VenusP-Valve (5-year CE follow-up data ...